Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis shows atezolizumab plus bevacizumab improves outcomes in unresectable hepatocellular carcinoma, suggesting expanded funding is beneficial.
Atezolizumab plus bevacizumab is cost-effective compared to lenvatinib and sorafenib across willingness-to-pay (WTP) values of one to three times Malaysia's GDP per capita. These findings provide evidence to inform public health policy that expanding funding and adoption of atezolizumab plus bevacizumab is likely to improve health outcomes cost-effectively.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: